Related references
Note: Only part of the references are listed.Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman et al.
CANCER DISCOVERY (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012
Andrea A. Florio et al.
CANCER (2020)
Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
Melanie A. Krook et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization
Michael Koehler et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.
James M. Cleary et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
Lipika Goyal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
Phillip C. C. Liu et al.
PLOS ONE (2020)
Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors
R. Bahleda et al.
ANNALS OF ONCOLOGY (2020)
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Hiroshi Sootome et al.
CANCER RESEARCH (2020)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma
Sarinya Kongpetch et al.
JCO GLOBAL ONCOLOGY (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
FGF/FGFR signaling pathway involved resistance in various cancer types
Yangyang Zhou et al.
JOURNAL OF CANCER (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2019)
Cholangiocarcinoma: Epidemiology and risk factors
Shahid A. Khan et al.
LIVER INTERNATIONAL (2019)
Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
Joon Oh Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC plus mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
Angela Lamarca et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.
David Michael Hyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2019)
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai et al.
CELLS (2019)
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro et al.
BRITISH JOURNAL OF CANCER (2019)
TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
Maria Kalyukina et al.
CHEMMEDCHEM (2019)
FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies
Vivek Subbiah et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Systemic therapy for gallbladder cancer
Milind Javle et al.
CHINESE CLINICAL ONCOLOGY (2019)
Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy
Melanie A. Krook et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2019)
O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors
F Meric-Bernstam et al.
ANNALS OF ONCOLOGY (2018)
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2018)
Future applications of FGF/FGFR inhibitors in cancer
Gaia Cristina Ghedini et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways
Xu-Xiao Chen et al.
CELL DEATH & DISEASE (2018)
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype
Apurva Jain et al.
JCO PRECISION ONCOLOGY (2018)
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2017)
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy P. S. Perera et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach
Marco Presta et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Apinya Jusakul et al.
CANCER DISCOVERY (2017)
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshad Farshidfar et al.
CELL REPORTS (2017)
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten et al.
CLINICAL CANCER RESEARCH (2016)
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Chiara Degirolamo et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. W. Valle et al.
ANNALS OF ONCOLOGY (2016)
Forty-Year Trends in Cholangiocarcinoma Incidence in the US: Intrahepatic Disease on the Rise
Supriya K. Saha et al.
ONCOLOGIST (2016)
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
Terence G. Hall et al.
PLOS ONE (2016)
Targeting FGFR Signaling in Cancer
Mehdi Touat et al.
CLINICAL CANCER RESEARCH (2015)
Genetics of Opisthorchis viverrini-related cholangiocarcinoma
Apinya Jusakul et al.
CURRENT OPINION IN GASTROENTEROLOGY (2015)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
Cell Lineage Tracing Reveals a Biliary Origin of Intrahepatic Cholangiocarcinoma
Rachel V. Guest et al.
CANCER RESEARCH (2014)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
Rondell P. Graham et al.
HUMAN PATHOLOGY (2014)
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater et al.
JOURNAL OF HEPATOLOGY (2014)
The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
Yoshito Nakanishi et al.
MOLECULAR CANCER THERAPEUTICS (2014)
New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
Jeffrey S. Ross et al.
ONCOLOGIST (2014)
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
Mitesh J. Borad et al.
PLOS GENETICS (2014)
Fibroblast growth factor (FGF) signaling in development and skeletal diseases
Chad M. Teven et al.
GENES & DISEASES (2014)
TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities
Hiroaki Ochiiwa et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers
Waraporn Chan-on et al.
NATURE GENETICS (2013)
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Yuchen Jiao et al.
NATURE GENETICS (2013)
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Yi-Mi Wu et al.
CANCER DISCOVERY (2013)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
Vito Guagnano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
T. Okusaka et al.
BRITISH JOURNAL OF CANCER (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1
Jyothsna Gattineni et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1α-hydroxylase expression in vitro
Farzana Perwad et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
Cellular signaling by fibroblast growth factor receptors
VP Eswarakumar et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Share Paper
